A Combined Pharmacometrics Analysis of Biomarker Distribution Under Treatment With Standard- or Low-Dose Rivaroxaban in Real-World Chinese Patients With Nonvalvular Atrial Fibrillation

• Ngā kaituhi matua: Nan Zhao (Author), Zhiyan Liu (Author), Qiufen Xie (Author), Zhe Wang (Author), Zhongyi Sun (Author), Qian Xiang (Author), Yimin Cui (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: The rivaroxaban dose regimen for patients with nonvalvular atrial fibrillation (NVAF) is complex in Asia. Given the high interindividual variability and the risk of bleeding caused by rivaroxaban in Asians, the influencing factors and the relationship between outlier biomarkers and bleed...